Please login to the form below
30
Revenue 2017Botox/Neuromodulator
The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Botox/Neuromodulator was produced by Allergan.
Pharma funding and M&A in 2020
a cool $63bn (which was also notable for putting the world’s best-selling drug Humira under the same roof as Botox).
Lundbeck gets US approval for migraine drug at heart of Alder takeover
specialists aren’t rushing to switch wholesale from other migraine preventative therapies like Allergan’s Botox.
20 for 2020 – Five pharma companies to watch
year. Botox is facing tougher competition in the market from new migraine drugs as well as rivals in its medical aesthetics indications. ... The latter is still low level, however, and biosimilars to Botox are thought to be some years off the market.
Revenue growth at Ipsen numbs pain of palovarotene calamity
as Dysport (abobotulinumtoxinA), a rival to Allergan’s big-selling Botox brand.
Botox strength bolsters Allergan ahead of AbbVie takeover
The US specialised therapeutics business – which include Botox – posted just 0.7% growth in the quarter to $1.82bn as medical aesthetics products Juvederm and Restasis posted sales declines. ... AbbVie has already announced plans to spin off the
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Subscribe to our email news alerts
Featured jobs
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- ASH 2022: bad blood but big advances
- MIT researchers develop AI model to detect future lung cancer risk
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Eli Lilly announces $450m investment in US manufacturing site
- Fishawack Health welcomes Mario Muredda as its new President of Marketing
- Pharmaceutical Marketing Strategies For The Digital Age
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- Roche’s Polivy recommended by NICE for lymphoma therapy
- A bundle of nerves
- GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
PMHub
AMICULUM
AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >300 healthcare communications professionals,...
Latest intelligence
- Pharmaceutical Marketing Strategies For The Digital Age
- In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...
- The challenges of identifying rare diseases
- With increased awareness and improved diagnosis, more rare diseases are being recognised and this number is likely to increase in the coming years...
- 5 ways we’re enhancing our services to support our clients in 2023
- Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023....
